Population versus individual protection by pneumococcal conjugate vaccination

In *The Lancet*, Laura Hammitt and colleagues describe a reduction of pneumococcal disease burden in all ages by childhood immunisation with ten-valent pneumococcal conjugate vaccine (PCV) in Kenya, a low-income country (LIC), which adds to the body of evidence for this effect, which is well described to date only in high-income and middle-income countries.

Their longitudinal surveillance study established a comprehensive clinical and microbiological surveillance system within the Kilifi Health and Demographic

Comment

stopping, convulsion can stutter or peter out rather than cease abruptly. Video recording and masked reassessment of the outcomes in ConSEPT was used as an innovative quality assessment tool to mitigate this weakness. This process and ultimately a result different from that for which the investigators had hoped in both trials suggest that this potential source of bias did not drive the findings of the trials. The subjectivity of the clinical outcome, however, persists. On the one hand, clinical response to therapy is the only patient-oriented outcome that matters. On the other hand, clinical response to therapy is a black box. The relevant contributions of several factors cannot be directly observed or known in these studies. Subjectivity not only complicates clinical determination of cessation of seizures but also complicates subsequent clinical decision making about when to use additional rescue doses of anticonvulsants and when to proceed to endotracheal intubation. Similar clinical outcomes with both drugs in these trials might indicate a similar pharmacological effect on seizures but alternatively might show that clinical factors other than the drugs might be driving the clinical outcome more strongly. If so, research to improve clinical outcomes might have to assess more than just the choice of medication.

As we move forward, discovery will require innovations that attempt to disentangle the effects of pharmacology, electrophysiology, and clinical decision making on clinical response. For example, we will need new technology to practically acquire and interpret electroencephalography in the earliest phases of emergency care in both practice and research. Clinical trials can also expand the use of video monitoring or develop other innovations to better understand practice variability with regard to whether patients undergo endotracheal intubation during or after seizures.

There are good reasons to believe that how we treat children (and adults) with convulsive status epilepticus in the first minutes and hours after ictus is critically important. ConSEPT and EcLiPSE are one step towards learning how best to care for these patients.

*Robert Silbergleit, Jordan J Elm*
Department of Emergency Medicine, University of Michigan, Ann Arbor, MI 48103, USA (RS); Data Coordination Unit, Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC, USA (JJE) robert.silbergleit@umich.edu

We are both Principal Investigators of the ESETT clinical trial, which is funded by the US National Institutes of Health, with overlapping goals to the reported trials. ESETT has completed enrolment but has not yet been published. We declare no other competing interests.

Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license.

1. Aldredge BK, Gelb AM, Isaacs SM, et al. A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus. N Engl J Med 2001; 345: 631–37.
2. Chamberlain JM, Okada P, Holti M, et al. Lorazepam vs diazepam for pediatric status epilepticus: a randomized clinical trial. JAMA 2014; 311: 1652–60.
3. Silbergleit R, Durkalski V, Lowenstein D, et al. Intramuscular versus intravenous therapy for prehospital status epilepticus. N Engl J Med 2012; 366: 591–600.
4. Brophy GM, Bell R, Claassen J, et al. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care 2012; 17: 3–23.
5. Glaser T, Shinnar S, Gloss D, et al. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the Guideline Committee of the American Epilepsy Society. Epilepsy Curr 2016; 16: 48–61.
6. Dalziel SR, Borland ML, Frynj, J, et al. Levetiracetam versus phenytoin for second-line treatment of convulsive status epilepticus in children (ConSEPT): an open-label, multicentre, randomised controlled trial. Lancet 2013; published online April 17. http://dx.doi.org/10.1016/S0140-6736(13)60722-6.
7. Lyttle MD, Rainford NEA, Gambrel C, et al. Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial. Lancet 2013; published online April 17. http://dx.doi.org/10.1016/S0140-6736(13)60724-X.
8. Bleck T, Cook H, Chamberlain J, et al. The established status epilepticus trial 2013: Epilepsia 2013; 54: 89–92.
9. Connor JT, Elm JJ, Broglio KR, ESETT and ADAPT-IT Investigators. Bayesian adaptive trials offer advantages in comparative effectiveness trials: an example in status epilepticus. J Clin Epidemiol 2012; 66: 5520–27.
10. Guterman EL, Burke JF, Josephson SA, Beltmann JP. Institutional factors contribute to variation in intubation rates in status epilepticus. Neurohospitalist 2018; published online Dec 18. DOI:10.1177/1941847118813549.
Surveillance System (KHDSS) that encompassed a population of 284826 in 2016, where blood and cerebrospinal fluid were obtained using a detailed protocol in individuals admitted to the sole government hospital; cross-sectional nasopharyngeal (NP) carriage surveys were conducted annually on 500 randomly selected individuals of all ages, and vaccination data were linked to children’s identification in the KHDSS at the 26 clinics administering vaccines. Using this thorough surveillance system, Hammitt and colleagues\(^1\) show significant reductions in vaccine-type (VT) invasive pneumococcal disease (IPD) and VT carriage in all age groups, although VT carriage persisted in 6% of children younger than 5 years of age. In Hammitt and colleagues’ study, introduction of the ten-valent pneumococcal conjugate vaccine with a catch-up campaign for children younger than 5 years and without a booster dose reduced the incidence of VT IPD in children aged up to 5 years by 92% (95% CI 78–97) and in unvaccinated children by 74% (41–89) in the 5–14-year age group and by 81% (49–93) in the 15 years and older age group. The strength of this study lies in the establishment of the surveillance and laboratory systems, and their linkage to a well functioning health and demographic surveillance system, leading to high-quality, reliable evidence of vaccine effectiveness. The major limitation to extending this study to other LICs is that although direct measurement of changes in IPD is important to assess vaccine effectiveness and the effect of serotype replacement,\(^1\)\(^-\)\(^3\) the need for a well established infrastructure that includes policies to obtain blood and cerebrospinal fluid samples and sophisticated microbiology laboratories, presents a formidable challenge in many LICs. NP carriage is easier to detect and evaluation of reductions in VT carriage, as also reported by Hammitt and colleagues,\(^1\) can provide a surrogate marker of PCV effectiveness and herd protection in LICs.

Hammitt and colleagues\(^1\) show the effect of the PCV10 programme on IPD and the similar effect on NP carriage, both in vaccinated and unvaccinated populations, thus adding to extensive data that herd protection is induced by prevention of transmission of PCV serotypes, which is mediated by reduction in carriage. This study also supports the evidence that reduction in VT carriage among children aged 3–5 years, who were part of the catch-up population in Kilifi, might be the best predictor of reductions in invasive pneumococcal disease among all ages.\(^4\) The importance of these inferences from Hammitt’s study is that they would allow cross-sectional measurement of VT carriage in children aged younger than 5 years following PCV programme implementation, which is a valuable tool, and perhaps the only widely accessible tool to assess new strategies to sustain immunisation programmes in LICs, especially those graduating from financial support from Gavi, the Vaccine Alliance.

As noted by Hammitt and colleagues,\(^1\) the residual VT colonisation in Kilifi is higher than that seen in high-income countries such as the USA\(^5\) and the UK,\(^6\) where booster dose-containing schedules, either three or four doses (2+1 or 3+1), lead to residual VT carriage in less than 5% of children younger than 5 years. A rapid decrease in VT carriage was seen in this age group in South Africa, a middle-income country, where only 1 year after implementation of a three-dose booster-containing schedule, VT colonisation in children aged 3 months to 2 years decreased from 40.8% to 13.8%.\(^7\) By contrast, data from Mozambique 2 years post implementation of a three-dose PCV regimen administered at 6, 10, and 14 weeks of age without a booster and without catch-up (3+0) showed a residual VT carriage prevalence of 20.7%.\(^8\) Even in more mature PCV programmes in Malawi\(^9\) and The Gambia,\(^10\) which use a 3+0 schedule, residual VT carriage remains high at 16.5% (3 years after introduction) and 11.4% (5 years following introduction). The 6% residual VT carriage described by Hammitt and colleagues in children younger than 5 years in Kilifi may be secondary to rapid induction of herd protection due to catch-up vaccination of older children aged 1–5 years, despite the lack of administration of a booster dose.

Although the benefits of a catch-up PCV programme are apparent here in Kilifi, contributing to data that have led Gavi to belatedly accept catch-up as an introduction strategy, the long-term effect of this approach on residual VT transmission is unknown, and a more affordable long-term approach, such as a 2+1 strategy, might be needed to achieve and maintain population protection. In countries with low levels of VT disease and carriage, a further iteration of population protection might be to eliminate a further infant dose for a 1+1 strategy, as suggested by the UK\(^11\)—provided that the second dose is a booster—to maintain population protection through low levels of VT carriage in children. For countries without boosters, a population-based approach might be to first change to the three-dose booster containing
Sham trials: benefits and risks for cardiovascular research and patients

Randomised, double-blind, placebo-controlled trials are considered the gold standard to evaluate efficacy and safety of new therapies. The reason behind blinding and placebo control is to minimise bias while balancing potential placebo effects. In the case of interventional procedures, the term placebo is replaced by sham procedures. Despite limited precedents, sham-controlled studies are becoming an expected norm for regulatory approval of new medical device therapies in certain therapeutic fields, of which hypertension is a central example.

The first report, to our knowledge, of a cardiovascular sham-controlled trial, in the 1950s, investigated the internal mammary artery ligation for the treatment of subjective refractory angina. Patients in the treatment group and sham-control group benefited alike. This trial ushered in a new era of sham procedures to investigate presumed effective procedures with subjective and objective endpoints. Recently, two studies, Objective Randomised Blinded Investigation With Optimal Medical Therapy of Angioplasty in Stable Angina (ORBITA) and a controlled trial of renal denervation for resistant hypertension (Symplicity HTN-3), attracted attention beyond the scientific community.

ORBITA examined whether percutaneous coronary intervention (PCI) improves exercise time through its specific mechanism or through a sham effect. At 6 weeks, there was no significant difference between groups.